3.32
0.39 (13.31%)
| Previous Close | 2.93 |
| Open | 2.99 |
| Volume | 554,087 |
| Avg. Volume (3M) | 1,110,555 |
| Market Cap | 40,152,412 |
| Price / Book | 2.90 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2025 - 31 Mar 2025 |
| Diluted EPS (TTM) | -2.11 |
| Current Ratio (MRQ) | 0.210 |
| Operating Cash Flow (TTM) | -13.99 M |
| Levered Free Cash Flow (TTM) | -7.35 M |
| Return on Assets (TTM) | -115.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | NRX Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | 1.13 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 23.56% |
| % Held by Institutions | 6.05% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| One Wealth Management Investment & Advisory Services, Llc | 30 Sep 2024 | 15,041 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (Ascendiant Capital, 1,255.42%) | Buy |
| Median | 31.00 (833.74%) | |
| Low | 19.00 (HC Wainwright & Co., 472.29%) | Buy |
| Average | 31.50 (848.80%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 1.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 06 Jan 2025 | 31.00 (833.73%) | Buy | 3.51 |
| 02 Jan 2025 | 31.00 (833.73%) | Buy | 2.99 | |
| Ascendiant Capital | 02 Dec 2024 | 45.00 (1,255.42%) | Buy | 1.35 |
| HC Wainwright & Co. | 25 Nov 2024 | 19.00 (472.29%) | Buy | 1.31 |
| EF Hutton | 30 Oct 2024 | 31.00 (833.73%) | Buy | 1.43 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |